PATENT CLAIM ANALYSIS

Application Number: 16220799
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "04400A"]

Abstract:
Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.

Claim (Index 43):
A method of treating Duchenne muscular dystrophy, comprising administering to a patient in need thereof an effective amount of an antisense oligonucleotide of 28 bases comprising the base sequence of SEQ ID NO: 6, wherein the oligonucleotide specifically hybridizes to an exon 44 target region of the Dystrophin pre-mRNA and induces exon 44 skipping, wherein the antisense oligonucleotide is a morpholino antisense oligonucleotide and wherein the thymine bases are optionally uracil bases;\n or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 98.0
- Lexical Diversity: 1.04545
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14213607', '14858416', '13830253', '14852257', '14852264']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6272934783855175
- 35 USC 102 Novelty (BERT): 0.5617568334140086
- Combined Prediction Score: 0.6207398138883666
- Mean Citation Score: 387.526426
- Max Citation Score: 425.4231
- Similarity Product: 349.257902980113

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test